Mitokyne Inc. is building a pipeline of small molecules to modulate mitochondrial activity to treat neuromuscular, cardiovascular and metabolic diseases, starting with Orphan or hereditary indications.

Mitokyne is the brainchild of co-founder, President and CEO Kazumi Shiosaki, co-founder and former CEO of Epizyme Inc. Shiosaki is managing partner at MPM Capital, which seeded Mitokyne and led its $45 million series A round last October.